Novavax (NVAX) Releases Earnings Results, Misses Expectations By $-0.02 EPS

Novavax (NVAX) reported quarterly earnings results on Wednesday, May-4-2016. The company reported $-0.29 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.27. The company posted revenue of $4.20 million in the period, compared to analysts expectations of $10.02 million. The company’s revenue was down -57.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.10 EPS.

Many Wall Street Analysts have commented on Novavax. Chardan Capital Markets Initiated Novavax on Apr 4, 2016 to “Neutral”, Price Target of the shares are set at $5.75.

Novavax opened for trading at $5.3 and hit $5.33 on the upside on Monday, eventually ending the session at $5.32, with a gain of 1.53% or 0.08 points. The heightened volatility saw the trading volume jump to 51,67,311 shares. Company has a market cap of $1,438 M.

In a different news, on Feb 1, 2016, John Trizzino (SVP, Commercial Operations) purchased 5,855 shares at $3.63 per share price. According to the SEC, on Feb 1, 2016, John A Iii Herrmann (SVP, General Counsel) purchased 2,072 shares at $4.38 per share price. On Feb 1, 2016, Gregory M Glenn (SVP, Research and Development) purchased 2,369 shares at $4.38 per share price, according to the Form-4 filing with the securities and exchange commission.

Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).


Leave a Reply

Novavax - Is it time to Sell?

Top Brokerage Firms are advising their investors on Novavax. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.